{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:00:25Z","timestamp":1780394425100,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/jid.2014.362","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T11:12:28Z","timestamp":1418296348000},"page":"13-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic\/Spontaneous Urticaria"],"prefix":"10.1016","volume":"135","author":[{"given":"Keith C.P.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarif K.","family":"Jabbar-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2014.362_bb0010","doi-asserted-by":"crossref","first-page":"e14794","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase\u2014a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLOS One"},{"key":"10.1038\/jid.2014.362_bb0015","first-page":"34","article-title":"Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses","volume":"32","author":"Asero","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1038\/jid.2014.362_bb0020","first-page":"00657","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"S0091-6749","author":"Chang","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.362_bb0025","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.362_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archdermatol.2007.5","article-title":"Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients","volume":"144","author":"Delong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1038\/jid.2014.362_bb0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjd.13073","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal","volume":"171","author":"Durack","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.362_bb0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria","volume":"328","author":"Hide","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.362_bb0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.362_bb0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.362_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.362_bb0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O\u2019Donnell","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.362_bb0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2133.1999.02815.x","article-title":"Human leucocyte antigen class II associations in chronic idiopathic urticaria","volume":"140","author":"O\u2019Donnell","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.362_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0190-9622(99)70495-0","article-title":"Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies","volume":"40","author":"Sabroe","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.362_bb0075","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study","author":"Saini","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1038\/jid.2014.362_bb0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.362_bb0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15370548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15370548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:46:18Z","timestamp":1743975978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15370548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0022202X15370548"],"URL":"https:\/\/doi.org\/10.1038\/jid.2014.362","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic\/Spontaneous Urticaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2014.362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}